MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ:MLTX)

11.32 -0.09 (-0.74%)

Delayed Quote Updated: 11:00 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MoonLake Immunotherapeutics - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

MoonLake Immunotherapeutics' CFO Sells 39K Shares ↗

July 03, 2026

This clinical-stage biotech focused on Nanobody therapies reported a notable insider sale.

Via The Motley Fool

Topics Regulatory Compliance

Why MoonLake Immunotherapeutics Stock Wilted on Wednesday ↗

June 24, 2026

The biotech is floating a relatively sizable secondary share issue.

Via The Motley Fool

MoonLake Immunotherapeutics CFO Trims His Stake. Should Investors Be Concerned? ↗

June 04, 2026

This clinical-stage biotech focused on inflammatory diseases reported a notable insider sale amid a year of sharp share price declines.

Via The Motley Fool

Topics Regulatory Compliance

MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations ↗

January 09, 2026

Via Stocktwits

The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock? ↗

April 18, 2026

Focused on novel immunotherapies for inflammatory diseases, this biotech firm reported significant insider selling in its latest filing.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares ↗

April 07, 2026

Focused on immunology therapies, this clinical-stage biotech reported significant insider selling amid a challenging year for the stock.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗

March 16, 2026

This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.

Via The Motley Fool

Topics Regulatory Compliance

Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position ↗

February 25, 2026

Structure Therapeutics develops oral drugs for chronic diseases, with lead assets targeting diabetes, obesity, and cardiovascular care.

Via The Motley Fool

Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit ↗

February 25, 2026

This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of clinical-stage candidates.

Via The Motley Fool

Topics Regulatory Compliance

Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction ↗

February 25, 2026

Disc Medicine develops therapies for rare blood disorders, leveraging clinical-stage biotech expertise in red blood cell biology.

Via The Motley Fool

Topics Regulatory Compliance

Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today ↗

February 23, 2026

Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’.

Via Stocktwits

Topics Artificial Intelligence ETFs Government

MLTX Stock Jumps Over 10% Overnight As Spine Drug Trial Win Sets Stage For Investor Day Showdown ↗

February 22, 2026

Investors are now turning to Monday’s Investor Day for regulatory clarity, pipeline updates, and key 2026 catalysts.

Via Stocktwits

MLTX Stock Heads Into Investor Day With FDA Momentum – What Traders Should Watch Next Week ↗

February 19, 2026

The investor day update comes after a stock collapse last year following mixed Phase 3 VELA trial results that raised concerns about approval risk.

Via Stocktwits

Nasdaq, S&P 500 Futures Edge Higher Ahead Of Fed Minutes: Why NVDA, TSLA, AAPL, APLD, PANW Are On Traders' Radar Today ↗

February 18, 2026

Data from Stocktwits indicated retail sentiment was stabilizing for SPY and QQQ.

Via Stocktwits

Topics ETFs Economy Lawsuit

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗

February 17, 2026

Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day.

Via Stocktwits

MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event ↗

February 17, 2026

Some Stocktwits users voiced optimism for the inflammation-drug maker getting acquired by pharma giant Merck.

Via Stocktwits

Topics Intellectual Property

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

February 10, 2026

From ImageneBio, Inc.

Via GlobeNewswire

BioTech Breakout: MoonLake Up 30% On FDA Wins ↗

February 03, 2026

Via MarketBeat

MLTX Stock Erases Most Of 2025 Loses As Wall Street, Retail Bets On FDA Feedback For Sonelokimab ↗

January 15, 2026

The FDA said that the drug, which treats a chronic inflammatory skin disorder, could establish evidence without additional trials.

Via Stocktwits

MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation

January 09, 2026

MoonLake Immunotherapeutics (NASDAQ: MLTX) shares have experienced a dramatic resurgence this week, climbing over 40% following a pivotal regulatory update that has effectively cleared the path for its...

Via MarketMinute

Topics Intellectual Property

These stocks are gapping in today's session ↗

January 08, 2026

Via Chartmill

Why Did MLTX Stock Jump 45% In Pre-Market Today? ↗

January 08, 2026

The company said it received positive regulatory feedback from the U.S. FDA following a Type B meeting regarding a drug used to treat hidradenitis suppurativa, a chronic inflammatory skin disorder.

Via Stocktwits

Get insights into the top gainers and losers of Thursday's pre-market session. ↗

January 08, 2026

Via Chartmill

MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX

December 15, 2025

From DJS Law Group

Via Business Wire

MOONLAKE DECEMBER 15th DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm

December 15, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

December 15, 2025

From Faruqi & Faruqi, LLP

Via Business Wire

MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

December 15, 2025

From The Schall Law Firm

Via Business Wire

MOONLAKE CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm Before December 15th

December 13, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Deadline Soon: MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

December 12, 2025

From The Law Offices of Frank R. Cruz

Via Business Wire

MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces That MoonLake Immunotherapeutics Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit

December 12, 2025

Via TheNewswire.com

Topics Lawsuit

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.